Overview

Tech Summary

Promoter Holding

Posts

AJANTPHARM

10123456789,101234567897012345678940123456789.7012345678950123456789
-16.75 (-1.41%)
The current prices are delayed.Login/Sign Up to see live prices.
Previous Close: 1191.5
1D
5D
1M
3M
1Y
5Y
Today's low
1165.45
Today's high
1193.45
52 week low
1111.6
52 week high
2354
Volume
37410
About
Tech Summary
DMA(12)
₹1240.83
DMA(50)
₹1263.98
DMA(100)
₹1279.82
DMA(200)
₹1504.17
Fund Summary
Market Cap
₹15048.55 Cr.
Enterprise Value
₹14840.63 Cr.
No. of Shares
12.81
P/E
21.12
RoE
23.38
Debt/Equity
0
Valuations
PE Chart
141618202224
PB Chart
5.06.07.08.0
Promoter Holdings
Public : 8.14%
FII : 8.64%
DII : 12.74%
Promoter : 70.48%
Others : 0%
Charts
Debt/Equity
0.0000.0050.0100.0150.020
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
ROE vs ROCE
20253035
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
ROE
ROCE
Revenue vs Profitability (1000Cr.)
0.51.01.52.02.53.0
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
Revenue
Profit
Margins(%)
20253035
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
Net Margin
Gross Margin
About
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Price Target Potential
Brokerage
Motilal Oswal
Ajcon Global
Target
2500
2400
Potential
26.26%
36.99%
Stock Sentiments
100% Bullish
0% Bearish
7 live trades of Rs. 938,233.95
S
sahilsg
 
Reputation: 0 • 
Feb 2 2:52 PM
AJANTPHARM
10 Qty (S) Validity Over-₹114.5
g33k
 
Reputation: 0 • 
Jan 31 2:45 PM
AJANTPHARM
50 Qty (S) Validity Over-₹40
Posts by FrontPage Users
NewsBot-display-image
Reputation: 30,347  •  38 minutes ago
Buy Ajanta Pharmaceuticals; target of Rs 1385: ICICI Direct
Buy Ajanta Pharmaceuticals; target of Rs 1385: ICICI Direct
ICICI Direct is bullish on Ajanta Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1385 in its research report dated February 02, 2023.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Feb 4 12:13 AM
Buy Ajanta Pharma; target of Rs 1410: Motilal Oswal
Buy Ajanta Pharma; target of Rs 1410: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1410 in its research report dated February 01, 2023.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Feb 3 11:58 PM
Buy Ajanta Pharma; target of Rs 1400: YES Securities
Buy Ajanta Pharma; target of Rs 1400: YES Securities
YES Securities is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated February 02, 2023.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Feb 1 12:51 PM
SGX Nifty up 120 points; here's what changed for market while you were sleeping
SGX Nifty up 120 points; here's what changed for market while you were sleeping
Foreign portfolio investors (FPIs) on Tuesday net sold Indian shares worth a whopping Rs 5,439 crore, provisional data showed. DIIs on the other hand, net bought shares to the tune of Rs 4,506 crore.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jan 13 3:26 PM
Rs 6,000 crore bonanza! These 3 index heavyweights topped MFs’ shopping list in December
Rs 6,000 crore bonanza! These 3 index heavyweights topped MFs’ shopping list in December
Shares of HCL Technologies dropped sharply in December by more than 7%, after the company trimmed its revenue growth guidance for the current financial year, citing that higher-than-expected furloughs will affect growth in the second half of the year.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Dec 23, 2022 12:36 PM
Stocks in the news: Landmark Cars, RIL, Abans Holdings, Yes Bank, Wipro and Dronacharya Aerial
Stocks in the news: Landmark Cars, RIL, Abans Holdings, Yes Bank, Wipro and Dronacharya Aerial
Dalal Street will witness the debut of three company on Friday, December 23, 2022 including mainboard companies- Landmark Cars, and Abans Holdings- along withe SME player Dronacharya Aerial Innovations.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Dec 22, 2022 2:41 PM
We are in a classic ‘no direction’ market; can’t go fully bullish or bearish: Amit Khurana
We are in a classic ‘no direction’ market; can’t go fully bullish or bearish: Amit Khurana
“We are at the early stages of a credit cycle uptick. Corporate balance sheets are pretty strong and therefore we maintain that banks will be structurally overweight in this entire uptrend. The recent consolidation is more of a time decay as I see it and the largecap banks are doing pretty well and that follows through with some of the midsize and smaller banks including PSUs. ”
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Dec 22, 2022 2:26 AM
Promoter entities to sell 4.6% stake in Ajanta Pharma via block deal Thursday
Promoter entities to sell 4.6% stake in Ajanta Pharma via block deal Thursday
Through the sale the entities are looking at raising close to Rs 650 crore.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Nov 11, 2022 2:01 PM
Corporate Radar: Ajanta Pharma to trade ex-dividend, LIC, M&M results and more
Corporate Radar: Ajanta Pharma to trade ex-dividend, LIC, M&M results and more
Shares of Ajanta Pharma (Rs 7 per share), GMM Pfaudler (Re 1 per share), Siyaram Silk (Rs 4 per share) and Nikko Parks (Re 0.4 per share) will trade ex-dividend. Shares of GPT Infraprojects will trade ex-bonus in respect of the bonus share issue in the ratio of 1:1.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Nov 8, 2022 12:43 AM
Buy Ajanta Pharmaceuticals; target of Rs 1505: ICICI Direct
Buy Ajanta Pharmaceuticals; target of Rs 1505: ICICI Direct
ICICI Direct is bullish on Ajanta Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1505 in its research report dated November 04, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Nov 6, 2022 10:51 PM
Tech Mahindra among 10 stocks to trade ex-dividend this week
Tech Mahindra among 10 stocks to trade ex-dividend this week
Supreme Industries declared a special dividend of Rs 6/- per equity share. The stock shall trade ex-dividend on November 7, 2022. In the past 12 months, the company has declared an equity dividend amounting to Rs 18 per share. On Friday, the scrip was trading 1.63% higher at Rs 2,237.10, over its last days closing price of Rs 2201.30.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Nov 5, 2022 4:33 PM
Buy Ajanta Pharma; target of Rs 1560: Motilal Oswal
Buy Ajanta Pharma; target of Rs 1560: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1560 in its research report dated November 04, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Nov 4, 2022 2:36 AM
This smallcap pharma company declares 350% interim dividend; record date fixed
This smallcap pharma company declares 350% interim dividend; record date fixed
Payment of interim dividend of Rs 7/- (350%) per equity share on the face-value of Rs 2/- per share for the Financial Year 2022-23,” said the companys filing with the exchange.For the aforesaid dividend, the company has also fixed the record date as November 14. Also, the dividend payment date has been intimated as of or after November 24.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Nov 4, 2022 12:16 AM
Ajanta Pharma Q2 Results: Profit dips 20% YoY to Rs 156.6 crore
Ajanta Pharma Q2 Results: Profit dips 20% YoY to Rs 156.6 crore
The company had posted a consolidated net profit of Rs 195.94 crore in the same period last fiscal, Ajanta Pharma said in a regulatory filing.Consolidated revenue from operations stood at Rs 938.1 crore, as against Rs 884.8 crore in the year-ago period.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Oct 8, 2022 5:41 PM
Mind Over Money: Nothing wrong with chasing the crorepati dream! Key is to avoid behaviour bias, explains Abhijit Chokshi
Mind Over Money: Nothing wrong with chasing the crorepati dream! Key is to avoid behaviour bias, explains Abhijit Chokshi
However, it also depends upon the stocks you select, a majority of companies need constant active tracking as in monitoring their quarterly earnings, sectoral tailwinds, and actions of the management at periodic intervals, and doing it on a part-time basis is dangerous.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Oct 3, 2022 5:21 PM
Buy Ajanta Pharma, target price Rs 1495:  ICICI Direct
Buy Ajanta Pharma, target price Rs 1495: ICICI Direct
Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 16369.91 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Sep 30, 2022 5:26 PM
Buy Ajanta Pharma, target price Rs 1495:  ICICI Direct
Buy Ajanta Pharma, target price Rs 1495: ICICI Direct
Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 16207.83 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Sep 29, 2022 11:31 AM
Investors seek safety in a stable pharma amid recession fears
Investors seek safety in a stable pharma amid recession fears
Stocks such as Divi's Laboratories, Ipca, Dr Reddy's, Cipla, and Alkem Laboratories have gained between 2% and 4% in the past week. The sector was in a consolidation phase in the past year due to a decline in business growth post-Covid, and valuations dropped about a fifth.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Aug 4, 2022 2:56 AM
Ahead of Market: 10 things that will decide stock action on Thursday
Ahead of Market: 10 things that will decide stock action on Thursday
Ajit Mishra, VP - Research, Religare Broking, suggests maintaining focus on identifying stock-specific opportunities and utilizing any dip to accumulate. “At the same time, we recommend keeping a check on leveraged positions and preferring a hedged approach.”
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jul 31, 2022 7:33 PM
Buy Ajanta Pharmaceuticals; target of Rs 1495: ICICI Direct
Buy Ajanta Pharmaceuticals; target of Rs 1495: ICICI Direct
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1495 in its research report dated July 29, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
vijay jaria-display-image
Reputation: 30,203  •  Jul 25, 2022 12:04 AM

COMPANY NAME RESULT DATE
#AARNAV 28 Jul 2022
#AAVAS 28 Jul 2022
#ADFFOODS 28 Jul 2022
#ADHARSHILA 28 Jul 2022
#ADSL 28 Jul 2022
#AGI 28 Jul 2022
#AJANTPHARM 28 Jul 2022
#APARINDS 28 Jul 2022
#ARL 28 Jul 2022
#AURUM 28 Jul 2022
#BAJAJFINSV 28 Jul 2022
#BAJAJHLDNG 28 Jul 2022
#BBL ......read more
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jul 20, 2022 3:41 AM
Ahead of Market: 10 things that will decide D-Street action on Wednesday
Ahead of Market: 10 things that will decide D-Street action on Wednesday
Ajit Mishra, VP - Research, Religare Broking, said the recent bounce in laggards like IT and metal has further eased the pressure. "We maintain our positive yet cautious stance and prefer sectors like auto, FMCG and banking for long opportunities."
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jul 14, 2022 12:58 AM
Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct
Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct
Net Sales are expected to increase by 13.9 percent Y-o-Y (down 2.1 percent Q-o-Q) to Rs 852.3 crore, according to ICICI Direct.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jul 8, 2022 3:16 AM
Ahead of Market: 10 things that will decide D-St action on Friday
Ahead of Market: 10 things that will decide D-St action on Friday
Siddhartha Khemka, Head - Retail Research, Motilal Oswal Financial Services, attributed the rally to positive global cues, Brent crude falling to below $100/bbl and slower intensity of FII selling. “Healthy pre-quarterly updates also boosted market sentiments. Real estate stocks continued to be in focus on the back of strong demand in key markets.”
The Economic Times
Like
Comment
Share
Add a comment
Shubham Birar-display-image
Reputation: 14,042  •  Jul 5, 2022 2:21 PM

🌟 Important Triggers for the day.

⚫ SGX nifty near 15850 indicating flat to the positive opening of Nifty 50.

⚫ American Markets were closed yesterday, while Dow futures are currently up by 130 points.

⚫ LME copper at its 17-month low, among economic slowdown indications, it ......read more
All About Indices - chart - 10303213
13 Likes
2 Comments
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jun 23, 2022 4:51 PM
Hold Ajanta Pharma, target price Rs 1305:  ICICI Direct
Hold Ajanta Pharma, target price Rs 1305: ICICI Direct
Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 15564.46 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jun 23, 2022 1:38 AM
Hold Ajanta Pharmaceuticals; target of Rs 1305: ICICI Direct
Hold Ajanta Pharmaceuticals; target of Rs 1305: ICICI Direct
ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1305 in its research report dated June 22, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jun 19, 2022 5:01 PM
Bonus issues: These 5 stocks will see corporate action this week
Bonus issues: These 5 stocks will see corporate action this week
Shares of Baid Leasing will turn ex-bonus on Monday, and the record date for the same is Tuesday. The company had announced a bonus issue of 1:1 on May 4. The same company had announced a stock split from face value of Rs 10 to Rs 2 in April.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  Jun 17, 2022 11:16 PM
Team Prashant Jain's 10 top stock picks in May. Do you own any?
Team Prashant Jain's 10 top stock picks in May. Do you own any?
The fund house increased holding in the stock to 16 lakh shares in May from 6 lakh shares in April, a jump of 189 per cent. In value terms, the fund house held Rs 261 crore worth of Escorts Kubota shares compared with Rs 91 crore at the end of April, data compiled by ICICIdirect suggests.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  May 16, 2022 3:53 AM
Buy Ajanta Pharma; target of Rs 2378: Anand Rathi
Buy Ajanta Pharma; target of Rs 2378: Anand Rathi
Anand Rathi is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2378 in its research report dated May 11, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  May 13, 2022 3:03 AM
Buy Ajanta Pharma; target of Rs 2350: YES Securities
Buy Ajanta Pharma; target of Rs 2350: YES Securities
YES Securities is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2350 in its research report date May 10, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  May 12, 2022 9:53 PM
Buy Ajanta Pharmaceuticals; target of Rs 1955: ICICI Direct
Buy Ajanta Pharmaceuticals; target of Rs 1955: ICICI Direct
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1955 in its research report dated May 11, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  May 12, 2022 8:08 PM
Buy Ajanta Pharma; target of Rs 2080: Motilal Oswal
Buy Ajanta Pharma; target of Rs 2080: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 2080 in its research report dated May 10, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  May 11, 2022 5:01 PM
Buy Ajanta Pharma, target price Rs 2080:  Motilal Oswal
Buy Ajanta Pharma, target price Rs 2080: Motilal Oswal
Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 13758.77 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Comment
Share
Add a comment
EqmOptiontrading-display-image
Reputation: 828  •  May 11, 2022 2:34 PM

STOCKS in ACTION 11 May

La Tim Metal & Industries Limited fixes May 23, 2022 as record date for stock split

State Bank of India: approved raising $2 billion in single or multiple tranches through a public offer and/or private placement of senior unsecured notes in US dollar or......read more
3 Likes
1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  May 11, 2022 1:53 AM
Ajanta Pharma Q4 net profit falls 5% to Rs 151 crore
Ajanta Pharma Q4 net profit falls 5% to Rs 151 crore
The drug firm had reported a consolidated PAT (Profit After Tax) of Rs 159 crore in the January-March quarter of 2020-21 fiscal.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 30,347  •  May 11, 2022 1:41 AM
Ajanta Pharma Q4 Results: Net profit falls 5% to Rs 151 cr
Ajanta Pharma Q4 Results: Net profit falls 5% to Rs 151 cr
For the year ended March 31, 2022, the company posted a PAT of Rs 713 crore. It was Rs 654 crore in FY21. Revenue from operations rose to Rs 3,341 crore last fiscal as against Rs 2,890 crore in 2020-21.
The Economic Times
Like
Comment
Share
Add a comment
ResultsBot-display-image
Reputation: 20,269  •  May 9, 2022 12:30 AM

#AJANTPHARM will declare results on May 10, 2022
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
Eternal Trader-display-image
Reputation: 160  •  Apr 23, 2022 4:16 AM


Reasons .....behind Ajanta pharma?
--> most important point is that ........if we compare and analyze insider/ big movements in this share with respect to Earning yields forward, earning yields trailing, dividend yield, the Risk premium on trailing EPS then we can g......read more
1 Like
Comment
Share
Add a comment
S
Reputation: 0  •  Apr 21, 2022 7:49 AM
Like
Comment
Share
Add a comment
HarmonicsTraders-display-image
Reputation: 2,990  •  Apr 20, 2022 9:03 PM
link
YouTube
Share your videos with friends, family, and the world
www.youtube.com

IT Stocks Results Started ..TCS , INFY- Results Declared already . Where to Buy them for Long Term ??

✅ HT STOCK ANALYSIS ON ⤵️

👉 #TCS
👉 #INFY
👉ESCORTS
👉NDTV
👉THEMISMED
👉TTKHLTCARE
👉 KOTAKBANK
👉JYOTHYLAB
👉 #RELIANCE
👉SAKSOFT
👉CHAMAN LAL
👉 #COAL......read more
Like
Comment
Share
Add a comment
Technical Analysis -display-image
Reputation: 428  •  Apr 17, 2022 1:36 AM

#AJANTPHARM - DAY (18 APRIL)
🔺RESISTANCE - 1775, 1841
🔺SUPPORT - 1703, 1670
🔷IF IT BREAKS SUPPORT & SUSTAIN BELOW - 1721
🔷THEN AGAIN GO DOWN 🔽 NEXT SUPPORT 1703, 1670
✅IF IT TAKES SUPPORT & SUSTAIN ABOVE - 1721
✅THEN AGAIN GO UP 🔼 NEXT ......read more
Chartbusters - chart - 8719513
Like
Comment
Share
Add a comment
Load More Posts